These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 19502975)

  • 1. Effect of genetic factors on opioid action.
    Kosarac B; Fox AA; Collard CD
    Curr Opin Anaesthesiol; 2009 Aug; 22(4):476-82. PubMed ID: 19502975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Genetic polymorphisms and human sensitivity to pain and opioids].
    Nishizawa D; Nagashima M; Satoh Y; Tagami M; Ikeda K
    Masui; 2009 Sep; 58(9):1093-101. PubMed ID: 19764431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pain and genetics.
    Fernandez Robles CR; Degnan M; Candiotti KA
    Curr Opin Anaesthesiol; 2012 Aug; 25(4):444-9. PubMed ID: 22732422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic factors in pain and its treatment.
    Stamer UM; Stüber F
    Curr Opin Anaesthesiol; 2007 Oct; 20(5):478-84. PubMed ID: 17873601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current evidence for a genetic modulation of the response to analgesics.
    Lötsch J; Geisslinger G
    Pain; 2006 Mar; 121(1-2):1-5. PubMed ID: 16472919
    [No Abstract]   [Full Text] [Related]  

  • 6. Genetics of pain, opioids, and opioid responsiveness.
    Tremblay J; Hamet P
    Metabolism; 2010 Oct; 59 Suppl 1():S5-8. PubMed ID: 20837195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics in palliative care.
    Kleine-Brueggeney M; Musshoff F; Stuber F; Stamer UM
    Forensic Sci Int; 2010 Dec; 203(1-3):63-70. PubMed ID: 20709477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical implications of opioid pharmacogenetics.
    Argoff CE
    Clin J Pain; 2010 Jan; 26 Suppl 10():S16-20. PubMed ID: 20026961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Genetic variation-- important for the clinical effect of opioids?].
    Klepstad P; Dale O; Borchgrevink PC; Kaasa S; Skorpen F
    Tidsskr Nor Laegeforen; 2005 Oct; 125(19):2655-8. PubMed ID: 16215614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action.
    Lötsch J; Skarke C; Wieting J; Oertel BG; Schmidt H; Brockmöller J; Geisslinger G
    Clin Pharmacol Ther; 2006 Jan; 79(1):72-89. PubMed ID: 16413243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics in pain management: the clinical need.
    Webster LR
    Clin Lab Med; 2008 Dec; 28(4):569-79. PubMed ID: 19059063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can heterogeneity of chronic sickle-cell disease pain be explained by genomics? A literature review.
    Adegbola MA
    Biol Res Nurs; 2009 Jul; 11(1):81-97. PubMed ID: 19487302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined catechol-O-methyltransferase and mu-opioid receptor gene polymorphisms affect morphine postoperative analgesia and central side effects.
    Kolesnikov Y; Gabovits B; Levin A; Voiko E; Veske A
    Anesth Analg; 2011 Feb; 112(2):448-53. PubMed ID: 21127283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic variation and response to morphine in cancer patients: catechol-O-methyltransferase and multidrug resistance-1 gene polymorphisms are associated with central side effects.
    Ross JR; Riley J; Taegetmeyer AB; Sato H; Gretton S; du Bois RM; Welsh KI
    Cancer; 2008 Mar; 112(6):1390-403. PubMed ID: 18257092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetic treatments for drug addiction: alcohol and opiates.
    Haile CN; Kosten TA; Kosten TR
    Am J Drug Alcohol Abuse; 2008; 34(4):355-81. PubMed ID: 18584566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A genetic association study of the functional A118G polymorphism of the human mu-opioid receptor gene in patients with acute and chronic pain.
    Janicki PK; Schuler G; Francis D; Bohr A; Gordin V; Jarzembowski T; Ruiz-Velasco V; Mets B
    Anesth Analg; 2006 Oct; 103(4):1011-7. PubMed ID: 17000822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding the genetic determinants of pain and pain management.
    Miaskowski C
    Semin Oncol Nurs; 2009 May; 25(2 Suppl 1):S1-7. PubMed ID: 19447317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of CYP2D6 and OPRM1 pharmacogenetic testing for opioid therapy.
    Reynolds KK; Ramey-Hartung B; Jortani SA
    Clin Lab Med; 2008 Dec; 28(4):581-98. PubMed ID: 19059064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Postoperative pain management following orthognathic surgery in consideration of individual differences--is the antinociceptive effect of fentanyl related to the genotype involving nucleotide at OPRM1?].
    Fukuda K; Hayashida M; Ikeda K
    Masui; 2009 Sep; 58(9):1102-8. PubMed ID: 19764432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.